• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Pharmacological Research

    Pharmacological Research

    JournalISSN 1043-6618eISSN 1096-1186中科院 医学 2区

    年发文量

    研究主题

    论文(12279)

    排序
    1NewMetabolic Reprogramming in Hepatocellular Carcinoma: Liver-Specific Immune Dysfunction, Immunotherapy Resistance, and Translational Biomarker Development
    Chunyan Dai,Shengying Lou,Huali Luo, Qiuhong Fan, Danyang Luo,Guanhai Dai, Wanping Zhu,Xiangcheng Fan, Qinglin Li, Xiaojun Xu

    Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatment options for advanced HCC, responses remain heterogeneous because of both primary and acquired resistance. Metabolic reprogramming may shape these outcomes by altering nutrient availability, metabolite accumulation, antigen presentation, immune-cell fitness, stromal organization, and spatial immune access. This review provides an evidence-weighted assessment of major immunometabolic mechanisms in HCC, focusing on the glycolysis-hypoxia-lactate and tryptophan-kynurenine/IDO1 axes, lipid and cholesterol metabolism, purinergic signaling, mitochondrial and redox regulation, and ferroptosis. We emphasize that these pathways are context dependent, with effects determined by cellular source, differentiation state, spatial organization, and tumor-intrinsic versus immune-cell metabolic adaptation. Molecular heterogeneity, etiology, and cirrhosis are considered together, with WNT-β-catenin/CTNNB1-associated states illustrating their intersection with immune organization and ICI response. Because translational maturity varies widely, we distinguish mechanistic evidence, biomarker association, predictive validation, and clinical utility. We propose a framework integrating HCC specificity, primary human validation, cellular and spatial localization, causal immune-functional evidence, treatment-linked and longitudinal assessment, biomarker feasibility, and liver-specific safety. The framework also considers intervention timing and the distinction between primary and acquired ICI resistance. It may guide progression from metabolic discovery to spatially resolved mechanism, biomarker development, pharmacodynamic validation, and clinical evaluation while accounting for cirrhosis-associated remodeling, hepatic reserve, and treatment-related toxicity.

    2026
    引用
    AI阅读
    加入学术空间
    2NewImmunoPET-guided TIM-3 Theranostics Enables Dynamic Visualization of Adaptive Immune Escape and Targeted Radioimmunotherapy
    Jinping Tao,Ziqing Zeng,Jiayue Liu,Zhi Yang,Chuanke Zhao,Hua Zhu

    Suboptimal responses and adaptive resistance remain major hurdles to immunotherapy, necessitating noninvasive dynamic in vivo monitoring of emerging immune checkpoints and the subsequent development of targeted interventions. TIM-3 is closely associated with T-cell exhaustion and immunotherapy resistance. Nevertheless, no remarkable breakthroughs have been achieved in TIM-3-targeted therapeutic strategies. Here, we report a first-in-class TIM-3-targeted radio-theranostic platform based on the humanized anti-TIM-3 antibody T21(TQB2618), radiolabeled with 89Zr (zirconium-89) for immunoPET imaging and 177Lu (lutetium-177) for radionuclide therapy. 89Zr-T21 exhibited high TIM-3 affinity and target specificity at protein and cellular levels and enabled clear visualization of TIM-3-positive expression tumors. In a hTIM-3 humanized animal model, 89Zr-T21 initially showed dominant splenic uptake and limited tumor accumulation, consistent with a peripheral TIM-3 antigen sink, whereby abundant TIM-3-expressing immune cells sequester the tracer outside the tumor. Pre-administration of unlabeled T21 reduced splenic sequestration and optimized tumor visualization, with maximal tumor uptake achieved at a 25-fold pre-dosing level. Notably, 89Zr-T21 enabled longitudinal and noninvasive monitoring of immunotherapy-induced TIM-3 remodeling in vivo, revealing time-dependent TIM-3 upregulation following PD-1 blockade and dose-dependent TIM-3 expression changes after immunotherapy. The matched therapeutic agent 177Lu-T21 significantly inhibited A549hTIM-3 tumor growth with favorable safety. Collectively, this study establishes the first TIM-3-directed radio-theranostic framework for imaging adaptive immune resistance and advancing TIM-3 targeted radioimmunotherapy.

    2026
    引用
    AI阅读
    加入学术空间
    3NewGraph Learning Guided by Regulatory and Spatial Contexts Prioritizes Natural Compound–target Pairs in Digestive System Cancers
    Huizhong Jiang, Shihao Zheng, Chuanqi Yang, Xiaobei Zhang, Haixiao Liu,Yanju Bao
    2026
    引用
    AI阅读
    加入学术空间
    4NewTargeting ELF3 with Biomimetic Nanotherapy Sensitizes PDAC to Gemcitabine Via GSDME-mediated Pyroptosis
    Zoya Iqbal, Xin Zhang, Yikai Chen,Jinhai Zhang, Yuanchang Huang,A M Abd El-Aty,Xianbin Zhang, Xinxin Li

    Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal malignancy with limited effective treatment strategies due to modest intrinsic response to systemic chemotherapy. Moreover, the dense, fibrotic stroma and poor vasculature of pancreatic tumors severely restrict drug penetration and therapeutic efficacy. The transcription factor ELF3 acts as a key oncogenic driver that promotes tumor growth, metastasis, and chemoresistance. To address these delivery barriers and enhance therapeutic response, we developed a biomimetic nanoplatform using cancer cell membrane-coated ZIF-8 nanoparticles (CNPs) to co-deliver gemcitabine (GEM) and an ELF3-targeting shRNA (shELF3), aiming to improve tumor-targeting specificity and elucidate the underlying cell death mechanism. Efficient encapsulation of GEM and shRNA ELF3 within a biomimetic nanocarrier was successfully confirmed. In vitro evaluation demonstrated that GEM/shELF3-CNPs activated canonical caspase-3/gasdermin E (GSDME)-dependent pyroptosis, resulting in markedly enhanced cytotoxicity in 6606 PDA cells. Furthermore, in vivo administration yielded superior tumor accumulation, potent tumor growth suppression, and significantly prolonged survival in the murine PDAC model, alongside favorable biosafety profiles. Our findings demonstrate that combining ELF3 silencing with gemcitabine delivery via biomimetic nanocarriers presents a promising synergistic strategy to sensitize pancreatic tumors and enhance PDAC therapeutic outcomes. The graphical representation of the study is shown in Fig. 1.

    2026
    引用
    AI阅读
    加入学术空间
    5NewPIAS1 Mitigates Vascular Calcification Through Regulating Mitochondrial DNA Leakage Mediated by VDAC1-NLRX1 Axis in Diabetic Models
    Li Wang,Qianqian Huang,Wentao Liu, Baohang Xie, Aixia Zhao, Jiacheng Liu, Qi Wang, Liumei Meng, Mingyue Zhang, Yiqin Luo,Songqing Lai,Wenjun Wang,

    Vascular calcification, an important pathological process of cardiovascular remodeling, is primarily driven by the transition of vascular smooth muscle cells from contractile to osteogenic phenotype. Protein inhibitor of activated STAT1 (PIAS1) is closely associated with diabetes and vascular diseases, but its role and underlying mechanisms in the progression of diabetic vascular calcification (DVC) remain unclear. Herein, we investigated the role of PIAS1 in DVC by genetic modulation and explored its molecular mechanisms by transcriptomics and co-immunoprecipitation with mass spectrometry (Co-IP-MS). We demonstrate that PIAS1 expression is downregulated in both in vitro and in vivo DVC models; furthermore, PIAS1 overexpression alleviates DVC, whereas PIAS1 knockout exacerbates it. Mechanistically, Co-IP-MS analysis reveals an interaction between PIAS1 and voltage-dependent anion channel 1 (VDAC1), which enhances the SUMOylation of VDAC1 while inhibiting its oligomerization. PIAS1 also reduces the binding between NLR family member X1 (NLRX1) and VDAC1, ultimately attenuating mitochondrial DNA leakage into the cytoplasm. More importantly, we find that Ginsenoside Ro is a PIAS1-targeting natural product which alleviates DVC. These findings identify PIAS1 as a novel therapeutic target for DVC and provide a new candidate for DVC prevention and treatment.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 12279 篇论文

    高被引作者

    作者引用发文
    Robert Roskoski Jr.1028250
    Amirhossein Sahebkar536073
    Helmut Sies32831
    Ramarao Poduri30784
    Chaman Lal Kaul30404
    Bhoomi Viswanad26622
    Krishnamoorthy Srinivasan26131
    L Asrat26131
    Maciej Banach229836
    Pitchai Balakumar211327

    高产作者

    作者引用发文
    Amirhossein Sahebkar536073
    Robert Roskoski Jr.1028250
    Alfio Bertolini65142
    Alberto Corsini153042
    Liang Liu165041
    Stefano Govoni129840
    Hua Zhou144236
    Maciej Banach229836
    Leung Elaine Lai-Han117733
    Filippo Drago121233

    相关期刊

    Biomedicine & Pharmacotherapy
    European Journal of Pharmacology
    Life Sciences
    Pharmacology and Therapeutics
    Current pharmaceutical design
    Oxidative medicine and cellular longevity
    Signal transduction and targeted therapy
    Biomarker Research
    Phytomedicine
    International Immunopharmacology